

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1614

DENT ET AL.

APPLICATION NO: 10/510,531

FILED: MARCH 30, 2005

FOR: COMBINATION OF GLIVEC (STI571) WITH A CYCLIN-  
DEPENDENT KINASE INHIBITOR, ESPECIALLY FLAVOPIRIDOL  
IN THE TREATMENT OF CANCER

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

PETITION FOR EXTENSION OF TIME

Sir:

The Office Action of July 24, 2007 has a shortened statutory time set to expire on August 24, 2007. A five-month extension is hereby requested pursuant to 37 CFR §1.136(a).

Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$2230 for payment of the extension fee. An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees under 37 CFR §1.17 which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis.

Respectfully submitted,

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080

Date: 1/3/08

  
Oona A. Manzari  
Attorney for Applicants  
Reg. No. 48,152  
Phone No. (862) 778-7852